Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus

Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome

(2011) J. Cortés-Hernández et al.   BRITISH JOURNAL OF DERMATOLOGY

Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare

(2011) Inbal Braunstein et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018

(2010) Katherine E. Warren et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutaneous lupus erythematosus: Update of therapeutic options

(2010) Annegret Kuhn et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cutaneous lupus erythematosus: Update of therapeutic options

(2010) Annegret Kuhn et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Lenalidomide for the Treatment of Resistant Discoid Lupus Erythematosus

(2009) Asha Shah et al.   ARCHIVES OF DERMATOLOGY

A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus

(2009) G.B.E. Jemec et al.   BRITISH JOURNAL OF DERMATOLOGY

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD